Durvalumab: an investigational agent for unresectable hepatocellular carcinoma

References

• Islami F, Ward EM, and Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 1: national Cancer Statistics. J Natl Cance Inst. 2021;113:1648–1669.
   PubMedGoogle Scholar
• Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–491.e1.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology. 2018;68:723–750.
   PubMed Web of Science ®Google Scholar
• Farinati F, Vitale A, Spolverato G, et al. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006.
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. JCO. 2020;38:4317–4345.
   PubMed Web of Science ®Google Scholar
• Vitale A, Farinati F, Pawlik TM, et al. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. Liver Int. 2019;39:1478–1489.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–286.
   PubMed Web of Science ®Google Scholar
• Sun H-C, Tang Z-Y, Sun HC. Tang ZYAngiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004;130:307–319.
   PubMedGoogle Scholar
• Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8:292–301.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379:54–63.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–296.
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39:98–106.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche A. Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [Internet]. clinicaltrials.gov; 2021 [cited 2021 Nov 29]. Report No.: NCT03434379. Available from: https://clinicaltrials.gov/ct2/show/NCT03434379.
   Google Scholar
• Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma [Internet]. [cited 2021 accessed December 2021 Nov 30]. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14533.
   Google Scholar
• Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43:S54–62.
   PubMed Web of Science ®Google Scholar
• Gao B, Jeong W-I, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2008;47:729–736.
   PubMed Web of Science ®Google Scholar
• Le Bail B, Balabaud C, Bioulac-Sage P. Anatomy and Structure of the Liver and Biliary Tree. In: Prieto J, Rodés J, Shafritz DA, editors. Hepatobiliary Diseases [Internet]. Berlin Heidelberg:Springer; 1992 [cited 2021 Dec 7]. p. 1–38.Available from https://doi.org/10.1007/978-3-642-76802-6_1.
   Google Scholar
• Winau F, Hegasy G, Weiskirchen R, et al. Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses. Immunity. 2007;26:117–129.
   PubMed Web of Science ®Google Scholar
• Yu M-C, Chen C-H, Liang X, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004;40:1312–1321.
   PubMed Web of Science ®Google Scholar
• Meng F, Wang K, Aoyama T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:765–776.e3.
   PubMed Web of Science ®Google Scholar
• O’Rourke JM, Sagar VM, Shah T, et al. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24:4436–4447.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: moving Beyond Vascular Endothelial Growth Factor. Oncologist. 2015;20:660–673.
   PubMed Web of Science ®Google Scholar
• Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 2007;10:149–166.
   PubMedGoogle Scholar
• Chouaib S, Messai Y, Couve S, et al. Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape. Front Immunol. 2012;3:21.
   PubMed Web of Science ®Google Scholar
• Chew V, Lai L, Pan L, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900–E5909.
   PubMedGoogle Scholar
• Wu Y, Kuang D-M, Pan W-D, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57:1107–1116.
   PubMed Web of Science ®Google Scholar
• Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005;41:722–730.
   PubMed Web of Science ®Google Scholar
• Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415–1426.
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–2339.
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129:428–437.
   PubMed Web of Science ®Google Scholar
• Granito A, and Muratori L Lalanne, C, et al. Hepatocellular carcinoma in viral and Autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021 Jun 14;27(22):2994–3009.
   PubMed Web of Science ®Google Scholar
• Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880–4891.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhou J, Liu X, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2020;69:365–379.
   PubMedGoogle Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–3895.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765–772.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct 2;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538–5545.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–151.
   PubMed Web of Science ®Google Scholar
• Kudo M. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: basics and Ongoing Clinical Trials. Oncology. 2017;92(Suppl 1):50–62.
   PubMedGoogle Scholar
• Lindsten T, Lee KP, Harris ES, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 1993;151:3489–3499.
   PubMed Web of Science ®Google Scholar
• Friedline RH, Brown DS, Nguyen H, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009;206:421–434.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–413.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Boussiotis VA, Lorsbach RB, et al. CTLA-4 regulates induction of anergy in vivo. Immunity. 2001;14:145–155.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008 Jun;8(6):467–477.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Curiel T, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity. Nat Med. 2003 May;9(5):562–567.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174–17179.
   PubMed Web of Science ®Google Scholar
• Nazareth MR, Broderick L, Simpson-Abelson MR, et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007;178:5552–5562.
   PubMed Web of Science ®Google Scholar
• Mu C-Y, Huang J-A, Chen Y, et al. High expression of PD-L1 in lung cancer May contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2010;28:682–688.
   PubMedGoogle Scholar
• Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381–3385.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41:2314–2322.
   PubMed Web of Science ®Google Scholar
• Ballmaier M, Lehner F, Krüger C, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234–243.
   PubMedGoogle Scholar
• Wu K, Kryczek I, and Chen L, et al. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009;69:8067–8075.
   PubMed Web of Science ®Google Scholar
• Diehl L, Schurich A, Grochtmann R, et al. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology. 2008;47:296–305.
   PubMedGoogle Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015;3:1052–1062.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9:135–139.
   PubMed Web of Science ®Google Scholar
• Lee HT, Lee JY, Lim H, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7:5532.
   PubMed Web of Science ®Google Scholar
• Baverel PG, Dubois VFS, Jin CY, et al. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. Clin Pharmacol Ther. 2018;103:631–642.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919–1929. **Pivotal article for Durvalumab application in advanced solid tumors.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lesterhuis WJ, Kok P-S, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21:1213–1223.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Vicente D, and Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial. J Thorac Oncol. 2021;16:860–867.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:661–674.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939.
   PubMed Web of Science ®Google Scholar
• Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (Danube): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1574–1588.
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Oh D-Y, Dhani N, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:1431–1438.
   PubMed Web of Science ®Google Scholar
• Xie C, Duffy AG, Brar G, et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020;26:2318–2326.
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–152.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942–950.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279–1288.
   PubMed Web of Science ®Google Scholar
• Quintela-Fandino M, Holgado E, Manso L, et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 2020 Nov 11;22(1):124.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A Phase III, Randomized, Open-Label,Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer. [Internet]. clinicaltrials.gov; 2021 cited 2021 Nov 30. Report No.: NCT03732677. Available from: https://clinicaltrials.gov/ct2/show/NCT03732677.
   Google Scholar
• Mayadev J, Nunes AT, Li M, et al. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020;30:1065–1070.
   PubMed Web of Science ®Google Scholar
• GK. Abou-Alfa, Chan, SL, and Kudo, M et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology. 2022;40(Supp_4):379–379
   Google Scholar
• Zhao M. An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope [Internet]. clinicaltrials.gov; 2021 cited 2021 Dec 2. Report No.: NCT04945720. Available from: https://clinicaltrials.gov/ct2/show/NCT04945720.
   Google Scholar
• Guo R. The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC): a Prospective, Single-armed, Stage II Clinical Trial [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 7]. Report No.: NCT04961918. Available from: https://clinicaltrials.gov/ct2/show/NCT04961918.
   Google Scholar
• Saeed A. A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA) [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT03539822. Available from: https://clinicaltrials.gov/ct2/show/NCT03539822.
   Google Scholar
• MD MF. Phase II Trial of Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) With/Without Tremelimumab for Advanced Hepatocellular Carcinoma After Progression on Prior PD-1 Inhibition [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT04430452. Available from: https://clinicaltrials.gov/ct2/show/NCT04430452.
   Google Scholar
• Boston Scientific Corporation. An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC) [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT05063565. Available from: https://clinicaltrials.gov/ct2/show/NCT05063565.
   Google Scholar
• Kim YJ. A Single-arm, Open-label, Safety and Efficacy Study of Radioembolization With Yttrium-90 Microspheres in Combination With Durvalumab (MEDI4736) in Locally Advanced and Unresectable Hepatocellular Carcinoma (HCC) (SOLID) [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT04124991. Available from: https://clinicaltrials.gov/ct2/show/NCT04124991.
   Google Scholar
• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design [Internet]. clinicaltrials.gov; 2021 cited 2021 Dec 2. Report No.: NCT04522544. Available from: https://clinicaltrials.gov/ct2/show/NCT04522544.
   Google Scholar
• The University of Hong Kong. Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for Downstaging Hepatocellular Carcinoma for Hepatectomy [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT04988945. Available from: https://clinicaltrials.gov/ct2/show/NCT04988945.
   Google Scholar
• National Taiwan University Hospital. A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT04294498. Available from: https://clinicaltrials.gov/ct2/show/NCT04294498.
   Google Scholar
• National Cancer Institute (NCI). A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC) [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 1]. Report No.: NCT03937830. Available from: https://clinicaltrials.gov/ct2/show/NCT03937830.
   Google Scholar
• Wainberg, ZA , Segal, NH , Jaeger, D et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J Clin Oncol [Internet]. 2021;35:4071. .
   Google Scholar
• Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. JCO. 2017;35:4073.
   Web of Science ®Google Scholar
• Kelley RK, Sangro B, and Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39:2991–3001.
   PubMed Web of Science ®Google Scholar
• Hilmi M, Neuzillet C, Calderaro J, et al. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7:333.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139–148.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.
   PubMed Web of Science ®Google Scholar
• Dong Y, Wong JSL, Sugimura R, et al. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel). 2021;13:1949.
   PubMedGoogle Scholar
• Granito A, Forgione A, Marinelli, S et al, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959.
   Web of Science ®Google Scholar
• Iyer RV, Li D, Dayyani F, et al. A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma. JCO. 2020;38:e16599–e16599.
   Google Scholar
• AVEO Pharmaceuticals, Inc. A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 2]. Report No.: NCT03970616. Available from: https://clinicaltrials.gov/ct2/show/NCT03970616.
   Google Scholar
• Bang Y-J, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020;137:272–284.
   PubMed Web of Science ®Google Scholar
• Saeed, A , Phadnis, M , Park, R et al A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA). J Clin Oncol [Internet]. 2021;38:4563.
   Google Scholar
• RenJi Hospital. Safety and Efficacy Study of Durvalumab in Combination With Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma– DULECT2020-1 Trial [Internet]. clinicaltrials.gov; 2020 [cited 2021 Nov 30]. Report No.: NCT04443322. Available from: https://clinicaltrials.gov/ct2/show/NCT04443322.
   Google Scholar
• AstraZeneca. A Phase III, Randomized, Double-Blind,Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation [Internet]. clinicaltrials.gov; 2021 [cited 2021 Nov 30]. Report No.: NCT03847428. Available from: https://clinicaltrials.gov/ct2/show/NCT03847428. *Ongoing phase III study to evaluate the role of Durvalumab in combination with Bevacizumab in adjuvant settings.
   Google Scholar
• Restrepo CR, Field DH, Kim AY. Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. J Vasc Interv Radiol. 2020;31:1740–1744.e9.
   PubMedGoogle Scholar
• Viveiros P, Riaz A, Lewandowski RJ, et al. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel). 2019;11:E1085.
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914–921.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A Phase III, Randomized, Double-blind,Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) [Internet]. clinicaltrials.gov; 2021 [cited 2021 Nov 30]. Report No.: NCT03778957. Available from: https://clinicaltrials.gov/ct2/show/NCT03778957.
   Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab [Internet]. clinicaltrials.gov; 2021 [cited 2021 Nov 30]. Report No.: NCT03638141. Available from: https://clinicaltrials.gov/ct2/show/NCT03638141.
   Google Scholar
• Ren Z-G. A Single-Arm Open-Label Pilot Study of Combination Therapy of TACE and Ablation With Durvalumab in A Selected Hepatocellular Carcinoma Population at Intermediate Stage [Internet]. clinicaltrials.gov; 2021 [cited 2021 Nov 30]. Report No.: NCT04517227. Available from: https://clinicaltrials.gov/ct2/show/NCT04517227.
   Google Scholar
• Choi C, Yoo GS, Cho WK, et al. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol. 2019;25:2416–2429.
   PubMed Web of Science ®Google Scholar
• Tak KY, Nam HC, Choi JY, et al. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings. Int J Cancer. 2020;147:1970–1978.
   PubMedGoogle Scholar
• Lee DVHF. A Multi-centre Single-arm Phase II Study on Durvalumab (MEDI 4736) With Stereotactic Body Radiation Therapy (SBRT) in Patients With Inoperable/Unresectable Hepatocellular Carcinoma [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 1]. Report No.: NCT04913480. Available from: https://clinicaltrials.gov/ct2/show/NCT04913480.
   Google Scholar
• Hong TS. A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 1]. Report No.: NCT03482102. Available from: https://clinicaltrials.gov/ct2/show/NCT03482102.
   Google Scholar
• Abou-Alfa G K et al . (2022). Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. JCO, 40(4_suppl), 379–379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• The University of Hong Kong. Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy [Internet]. clinicaltrials.gov; 2020 [cited 2021 Dec 1]. Report No.: NCT03817736. Available from: https://clinicaltrials.gov/ct2/show/NCT03817736.
   Google Scholar
• Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy - Full Text View - ClinicalTrials.gov [Internet]. [cited 2021 accessed December 2021 Dec 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03817736.
   Google Scholar
• Gao Q, Wang X-Y, Qiu S-J, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971–979.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129.
   PubMed Web of Science ®Google Scholar
• Scheiner B, Pomej K, and Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2021 76 353–363 ; S0168-8278(21)02100-0.
   PubMedGoogle Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: a Review. JAMA Oncol. 2016;2:1346–1353.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377–2385.
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320–341.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.
   PubMed Web of Science ®Google Scholar
• Fisher J, Zeitouni N, Fan W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2020;82:1490–1500.
   PubMed Web of Science ®Google Scholar
• Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J. 2018;6:970–973.
   PubMed Web of Science ®Google Scholar
• Shi G-M, Wang J, Huang X-W, et al. Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transpl. 2021;27:444–449.
   PubMedGoogle Scholar
• Sohal D. Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant [Internet]. clinicaltrials.gov; 2021 [cited 2021 Dec 1]. Report No.: NCT05027425. Available from: https://clinicaltrials.gov/ct2/show/NCT05027425.
   Google Scholar
• Sonpavde GP, Grivas P, Lin, Y et al, et al. Immune related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol. 2021 Jul;17(19):2545–2558.
   PubMedGoogle Scholar
• Julien K. Nivolumab in Advanced Hepatocellular carcinoma: safety Profile and Select Treatment- Related Adverse Events from the CheckMate 040 Study. Oncologist. 2020 Oct;25(10):e1532–e1540.
   PubMedGoogle Scholar
• Cabibbo, G, Lai, Q, Aghemo, Aet al 2022 doi:https://doi.org/10.1016/j.dld.2022.01.122 Optimizing systemic therapy for advanced hepatocellular carcinoma: The key role of liver function. Dig Liver Dis
   Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, and Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2021;S0168-8278(21):02223–02226 ; S0168827821022236.
   Google Scholar